Extended Data Table 6 Overview subsequent treatments in third line and higher

From: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

  1. Overview of subsequent treatments among patients who discontinued second-line endocrine therapy. The table contains numbers of all subsequent treatment lines, meaning third-line of treatment and thereafter. Numbers can add to more than 100% as patients could receive more than 1 subsequent treatment line. A patient was counted only once in one of the medication types. aUsed as the denominator for the percentages in the following sub-treatments. bUsed as the denominator for the percentages in the following sub-treatments. cTaselisib in combination with tamoxifen. dAbemaciclib monotherapy. e1Atezolizumab, Bevacizumab, Olaparib, Lenvatinib, Trastuzumab. e2Bevacizumab, Olaparib, Pembrolizumab, Pertuzumab + Trastuzumab.
Back to article page